ALFRED PASIEKA / SCIENCE PHOTO LIBRARY ALFRED PASIEKA / SCIENCE PHOTO LIBRARY
Computer artwork of monoclonal antibodies, bi-specific T-cell engagers (BiTEs), acting against tumour cells. Blinatumomab (trade name) specifically targets the CD19 antigen present on B cells. Blinatumomab enables a patient's T cells to recognize malignant B cells. A molecule of blinatumomab combines two binding sites: a CD3 site for T cells and a CD19 site for the target B cells. CD3 is part of the T cell receptor. The drug works by linking these two cell types and activating the T cell to exert cytotoxic activity on the target cell.Blinatumomab is used as a second-line treatment against acute lymphoblastic leukemia. The image shows a cancer cell (red, down left) and an immune cell (blue, upper right) connected by the Blinatumomab bi-specific antibody.
Model release not required. Property release not required.